<生产厂家价格>

苯甲酸利扎曲坦

苯甲酸利扎曲坦用途

Rizatriptan 苯甲酸盐(Maxalt)是 5-HT1激动剂。

苯甲酸利扎曲坦名称

[ CAS 号 ]:
145202-66-0

[ 中文名 ]:
苯甲酸利扎曲坦

[ 英文名 ]:
Rizatriptan benzoate

[中文别名 ]:

[英文别名 ]:

Rizatriptan benzoate salt
Rizatriptan benzoate
Maxalt
Rizatrimptan benzoate
MFCD00866224
Rizatriptan

苯甲酸利扎曲坦生物活性

[ 描述 ]:

Rizatriptan 苯甲酸盐(Maxalt)是 5-HT1激动剂。

[ 相关类别 ]:

研究领域 >> 神经疾病

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 5-HT受体

信号通路 >> 神经信号通路 >> 5-HT受体

[参考文献]

[1]. Sciberras DG, et al. Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. Br J Clin Pharmacol. 1997 Jan;43(1):49-54.

苯甲酸利扎曲坦物理化学性质

[ 密度 ]:
1.21g/cm3

[ 沸点 ]:
504.8ºC at 760mmHg

[ 熔点 ]:
178-180°C

[ 分子式 ]:
C₂₂H₂₅N₅O₂

[ 分子量 ]:
391.466

[ 闪点 ]:
259.1ºC

[ 精确质量 ]:
391.200836

[ PSA ]:
87.04000

[ LogP ]:
3.29660

[ 外观性状 ]:
白色至灰白色结晶粉末

[ 蒸汽压 ]:
2.58E-10mmHg at 25°C

[ 折射率 ]:
1.645

[ 储存条件 ]:
-20°C Freezer

[ 水溶解性 ]:
水溶性：可溶；水溶解度：53 g/l ；可溶于：甲醇；微溶：乙醇；不溶：乙醚

苯甲酸利扎曲坦MSDS

详细MSDS(安全技术说明书)

苯甲酸利扎曲坦安全信息

[ 符号 ]:

GHS08

[ 信号词 ]:
Danger

[ 危害声明 ]:
H360

[ 警示性声明 ]:
P201-P280-P308 + P313

[ 危害码 (欧洲) ]:
C,Xi

[ 风险声明 (欧洲) ]:
R34:Causes burns.

[ 安全声明 (欧洲) ]:
S26-S36/37/39-S45

[ 危险品运输编码 ]:
3259

[ 海关编码 ]:
2933990090

苯甲酸利扎曲坦海关

[ 海关编码 ]: 2933990090

[ 中文概述 ]:
2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期

[ Summary ]:
2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

苯甲酸利扎曲坦文献

Evolution of paediatric off-label use after new significant medicines become available for adults: a study on triptans in Finnish children 1994-2007.

Br. J. Clin. Pharmacol. 71(6) , 929-35, (2011)

• Off-label use in children is widespread. New medicines lack marketing authorization for paediatric use, even when they represent significant therapeutic advantages and are intended for treatment of ...

An approach for rapid development of nasal delivery of analgesics--identification of relevant features, in vitro screening and in vivo verification.

Int. J. Pharm. 420(1) , 43-50, (2011)

Drug delivery via the nasal route is gaining increasing interest over the last two decades as an alternative to oral or parenteral drug administration. In the current study an approach for rapid ident...

Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders.

Cephalalgia 31(7) , 786-96, (2011)

The study was carried out to assess the efficacy and tolerability of rizatriptan orally disintegrating tablet (ODT) for treating acute migraine in patients who are non-responders to sumatriptan.Many m...

更多文献